717 related articles for article (PubMed ID: 16960139)
1. Rare diseases, orphan drugs, and orphaned patients.
Scheindlin S
Mol Interv; 2006 Aug; 6(4):186-91. PubMed ID: 16960139
[No Abstract] [Full Text] [Related]
2. Orphan drugs and orphan tests in the USA.
Thoene JG
Community Genet; 2004; 7(4):169-72. PubMed ID: 15692190
[No Abstract] [Full Text] [Related]
3. The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review.
Burke KA; Freeman SN; Imoisili MA; Coté TR
Clin Pharmacol Ther; 2010 Oct; 88(4):449-53. PubMed ID: 20856241
[TBL] [Abstract][Full Text] [Related]
4. The Minor Use and Minor Species Animal Health Act: past, present, and future.
Haley CJ
Food Drug Law J; 2006; 61(1):13-43. PubMed ID: 16838456
[No Abstract] [Full Text] [Related]
5. Adopting orphan drugs--two dozen years of treating rare diseases.
Haffner ME
N Engl J Med; 2006 Feb; 354(5):445-7. PubMed ID: 16452556
[No Abstract] [Full Text] [Related]
6. Regulators adopt more orphan drugs.
Reardon S
Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293
[No Abstract] [Full Text] [Related]
7. Health care policy. Reforming off-label promotion to enhance orphan disease treatment.
Liang BA; Mackey T
Science; 2010 Jan; 327(5963):273-4. PubMed ID: 20075234
[No Abstract] [Full Text] [Related]
8. The Orphan Drug Act Revisited.
Thomas S; Caplan A
JAMA; 2019 Mar; 321(9):833-834. PubMed ID: 30768155
[No Abstract] [Full Text] [Related]
9. Developing treatments for inborn errors: incentives available to the clinician.
Haffner ME
Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
[TBL] [Abstract][Full Text] [Related]
10. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
Liu BC; He L; He G; He Y
J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
[TBL] [Abstract][Full Text] [Related]
11. Rare opportunities appear on the horizon to treat rare diseases.
Torres C
Nat Med; 2010 Mar; 16(3):241. PubMed ID: 20208483
[No Abstract] [Full Text] [Related]
12. [Distribution of orphan drugs by the pharmacist of the Faculty of Veterinary Medicine].
Tijdschr Diergeneeskd; 2004 Jul 15-Aug 1; 129(14-15):486. PubMed ID: 15344826
[No Abstract] [Full Text] [Related]
13. Law and research could add up to profitable niche drugs.
Haefner B
Nature; 2007 Apr; 446(7138):856. PubMed ID: 17443162
[No Abstract] [Full Text] [Related]
14. "Creating hope" and other incentives for drug development for children.
Connor E; Cure P
Sci Transl Med; 2011 Jan; 3(66):66cm1. PubMed ID: 21248312
[TBL] [Abstract][Full Text] [Related]
15. Lucrative niches: how drugs for rare diseases became lifeline for companies.
Anand G
Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531
[No Abstract] [Full Text] [Related]
16. The routes to orphan drug designation--our recent experience at the FDA.
Lev D; Thorat C; Phillips I; Thomas M; Imoisili MA
Drug Discov Today; 2012 Feb; 17(3-4):97-9. PubMed ID: 22210120
[No Abstract] [Full Text] [Related]
17. Should off-label drug use be off-the-table?
Rivkees SA
J Pediatr Endocrinol Metab; 2007 Feb; 20(2):171-2. PubMed ID: 17396432
[No Abstract] [Full Text] [Related]
18. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?
Wellman-Labadie O; Zhou Y
Health Policy; 2010 May; 95(2-3):216-28. PubMed ID: 20036435
[TBL] [Abstract][Full Text] [Related]
19. Prescription for the Orphan Drug Act: the impact of the FDA's 1992 regulations and the latest congressional proposals for reform.
Clissold DB
Food Drug Law J; 1995; 50(1):125-47. PubMed ID: 10342989
[No Abstract] [Full Text] [Related]
20. Orphan drug regulations. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2013 Jun; 78(113):35117-35. PubMed ID: 23767079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
